Stock Analysis of Entera Bio Ltd (ENTX) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ENTX
Close 2.25
Change -0.060 / 2.60 %
Volume 21530.00
Vol Change -73319.00 / 77.30 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bearish
Growth Index Very Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index No Significant Stability


Fundamental View of Entera Bio Ltd
PE (TTM)

-10.35

Very Poor
Price / Book

7.97

Very Poor
Price / Sales

15.57

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

80516.93 K

Enterprise Value

69631.93 K

ROA (TTM)

-64.08

Very Poor
ROE (TTM)

-76.99

Very Poor
Net Margin (TTM)

-150.47

Very Poor
Revenue

89.55 %

14000.00
Net Profit

175.96 %

-9929.00 K
Debt to Equity

0.0129

Excellent
Altman Z Score

20.87

Excellent
Quick Ratio

0

Poor
Cash Ratio

10.10

Excellent


Highs/Lows of Entera Bio Ltd
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week2.32 3.02 % 0.513 % 2.452.0829-May-2430-May-24
Two Week2.44 7.79 % 0.486 % 2.462.0822-May-2430-May-24
One Month1.96 14.80 % 4.80 % 2.7681.916-May-2401-May-24
Three Month1.375 63.64 % 3.56 % 3.351.2512-Apr-2401-Mar-24
Six Months0.7099 216.95 % 15.54 % 3.350.5212-Apr-2429-Dec-23
One year0.793 183.73 % 26.26 % 3.350.5212-Apr-2429-Dec-23
Two year2.15 4.65 % 27.72 % 3.350.47212-Apr-2411-Nov-22
Five year3.45 34.78 % 91.77 % 3.350.47212-Apr-2411-Nov-22


Technical View of Entera Bio Ltd
RSI

48.41

Neutral
MACD

0.0448

Bearish
ADX

15.83

Bearish
Super Trend

2.73

Mild Bearish
Williams %R

-69.25

Neutral
CCI

-70.51

Neutral


EMA 5

2.31

Strong Bearish
EMA 15

2.34

Neutral
EMA 50

2.12

Bullish
EMA 100

1.77

Bullish
SMA 100

1.63

Bullish
SMA 200

1.15

Strong Bullish
SMA 5 / 20

2.31 / 2.40

Bearish
SMA 15 / 50

2.39 / 2.17

Bullish
SMA 50 / 200

2.17 / 1.15

Strong Bullish




Charts of Entera Bio Ltd


Returns of Entera Bio Ltd with Peers
Period / StockENTXONCYFORAMIST
1 Week-3.02%-1.83%-5.82%-12.28%
1 Mth14.80%-3.60%-0.956%-9.09%
3 Mth63.64%-6.14%-10.69%-10.71%
6mth216.95%-26.21%-4.43%-55.09%
1 Year183.73%-33.95%8.37%-61.93%
2 Year4.65%-8.55%-15.91%-73.26%
5 Years-34.78%-37.79%--92.75%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Entera Bio Ltd with Peers
Ratio / StockENTXONCYFORAMIST
PE-10.35-2.7824.94-293.14
P/B7.973.083.51449.73
ROA-64.08-75.445.93-59.05
ROE-76.99-110.5914.08-153.42
Debt To Equity0.01290.00480.9503.00
Revenue14000.00
89.55 % 		0
% 		31669.79 K
13.08 % 		4500.00 K
10.00 %
Net Income-9929.00 K
175.96 % 		-32357.00 K
30.29 % 		6161.03 K
123.72 % 		-59251.00 K
3.71 %


Technicals of Entera Bio Ltd with Peers
Technical / StockENTXONCYFORAMIST-
ADX15.8318.2612.0122.43
CMF0.402-0.143-0.582-0.343
MFI39.9522.3627.8647.66
RSI48.4141.7243.7730.71
MACD Abv SignalFalseFalseFalseFalse
Price Above 50 MATrueFalseFalseFalse-
Price Above 200 MATrueFalseFalseFalse-


About : Entera Bio Ltd

Address : Kiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002
Tel : 972 2 532 7151
URL : https://www.enterabio.com
Code : ENTX, ISIN : IL0011429839, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 28_Jun_2018
Employee Count : 17

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.


Note : All Data Generated at the End of Trading Hours (EOD Data)